Phase 1b/2 RCT | Niraparib plus nivolumab vs. niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer.

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

Online first: #Niraparib plus #nivolumab or niraparib plus #ipilimumab in patients with platinum-sensitive advanced #pancreaticcancer: a randomised, phase 1b/2 trial https://t.co/HBci82F8zp pic.twitter.com/E8Qo2Antzt

— The Lancet Oncology (@TheLancetOncol) July 8, 2022